GNI Group Ltd. (TYO:2160)
Japan · Delayed Price · Currency is JPY 2,863.00
+102.00 (3.69%)
Aug 27, 2026, 11:05 AM JST
GNI Group Revenue
GNI Group had revenue of 6.41B JPY in the quarter ending June 30, 2026, a decrease of -7.51%. This brings the company's revenue in the last twelve months to 26.53B, up 9.93% year-over-year. In the year 2025, GNI Group had annual revenue of 26.84B with 13.68% growth.
Revenue (ttm)
26.53B
Revenue Growth
+9.93%
P/S Ratio
6.85
Revenue / Employee
26.79M
Employees
990
Market Cap
181.71B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 26.84B | 3.23B | 13.68% |
| Dec 31, 2024 | 23.61B | -2.40B | -9.22% |
| Dec 31, 2023 | 26.01B | 8.59B | 49.33% |
| Dec 31, 2022 | 17.42B | 4.73B | 37.26% |
| Dec 31, 2021 | 12.69B | 2.92B | 29.85% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Nxera Pharma | 33.43B |
| PeptiDream | 19.20B |
| Heartseed | 3.03B |
| Japan Tissue Engineering | 2.52B |
| Cuorips | 128.00M |
| Renascience | 68.00M |
| Healios K.K. | 59.00M |
| Oncolys BioPharma | 28.55M |
GNI Group News
- 2 months ago - GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Position as a Global Biopharmaceutical Company - GlobeNewsWire